PNAS: From HIV to Cancer, IL-37 Regulates Immune System
Denver, CO - A University of Colorado Cancer Center study published in this month’s Proceedings of the National Academy of Sciences describes the activity of a recently discovered communication molecule of the body’s immune system, Interleukin 37 or IL-37. It has been known to limit inflammation and the current study reports its activity in the adaptive immune system: IL-37 inhibits the ability of the immune system to recognize and target new antigens.
“Knowing this mechanism that underlies IL-37’s effect on the immune system now allows us to study IL-37 function and perhaps dysfunction in a wide range of diseases,” says Mayumi Fujita, MD, PhD, investigator at the University of Colorado Cancer Center, associate professor in the CU School of Medicine Department of Dermatology, and the paper’s senior author.
For example, knowing that IL-37 helps to create overall immune system sensitivity could allow researchers to manipulate IL-37 levels to sensitize the immune system to recognize and target tumor tissue, or desensitize the immune system in auto-immune conditions like rheumatoid arthritis in which the immune system acts over-aggressively toward healthy tissue.
IL-37 is one of the 38 known interleukins that carry messages in the immune system. The current study shows that IL-37 works through the regulation of dendritic cells, which trap, process and present new antigens. Dendritic cells are formed in bone marrow and migrate to parts of the body that commonly come in contact with new antigens, for example skin or the lining of the gut. Immature dendritic cells are in a state of readiness, waiting at these common points of first contact to trap new antigens. Mature dendritic cells trap an antigen and then migrate with the antigen to lymph nodes where they work to coordinate the immune response to the new antigen. Continue>
Page | 1 2
Posted in: Pharma | March 13, 2014
Posted in: Pharma | December 3, 2014